Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Direct evidence that Bcr-Abl tyrosine kinase activity disrupts normal synergistic interactions between Kit ligand and cytokines in primary primitive progenitor cells.

Strife A, Wisniewski D, Liu C, Lambek CL, Darzynkiewicz Z, Silver RT, Clarkson B.

Mol Cancer Res. 2003 Jan;1(3):176-85.

3.

New understanding of the pathogenesis of CML: a prototype of early neoplasia.

Clarkson BD, Strife A, Wisniewski D, Lambek C, Carpino N.

Leukemia. 1997 Sep;11(9):1404-28. Review.

PMID:
9305592
4.

Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases.

Wisniewski D, Lambek CL, Liu C, Strife A, Veach DR, Nagar B, Young MA, Schindler T, Bornmann WG, Bertino JR, Kuriyan J, Clarkson B.

Cancer Res. 2002 Aug 1;62(15):4244-55.

5.

Multi-level effects of flt3 ligand on human hematopoiesis: expansion of putative stem cells and proliferation of granulomonocytic progenitors/monocytic precursors.

Gabbianelli M, Pelosi E, Montesoro E, Valtieri M, Luchetti L, Samoggia P, Vitelli L, Barberi T, Testa U, Lyman S, et al.

Blood. 1995 Sep 1;86(5):1661-70.

6.

Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors.

Hiwase DK, White DL, Powell JA, Saunders VA, Zrim SA, Frede AK, Guthridge MA, Lopez AF, D'Andrea RJ, To LB, Melo JV, Kumar S, Hughes TP.

Leukemia. 2010 Apr;24(4):771-8. doi: 10.1038/leu.2009.299.

PMID:
20130598
7.
8.
9.
11.

FLK-2/FLT-3 ligand regulates the growth of early myeloid progenitors isolated from human fetal liver.

Muench MO, Roncarolo MG, Menon S, Xu Y, Kastelein R, Zurawski S, Hannum CH, Culpepper J, Lee F, Namikawa R.

Blood. 1995 Feb 15;85(4):963-72.

12.

Chronic myelogenous leukemia primitive hematopoietic progenitors demonstrate increased sensitivity to growth factor-induced proliferation and maturation.

Bhatia R, Munthe HA, Williams AD, Zhang F, Forman SJ, Slovak ML.

Exp Hematol. 2000 Dec;28(12):1401-12.

PMID:
11146162
13.

Effects of the tyrosine kinase inhibitor AG957 and an Anti-Fas receptor antibody on CD34(+) chronic myelogenous leukemia progenitor cells.

Carlo-Stella C, Regazzi E, Sammarelli G, Colla S, Garau D, Gazit A, Savoldo B, Cilloni D, Tabilio A, Levitzki A, Rizzoli V.

Blood. 1999 Jun 1;93(11):3973-82.

14.

KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors.

Corbin AS, O'Hare T, Gu Z, Kraft IL, Eiring AM, Khorashad JS, Pomicter AD, Zhang TY, Eide CA, Manley PW, Cortes JE, Druker BJ, Deininger MW.

Cancer Res. 2013 Sep 15;73(18):5775-86. doi: 10.1158/0008-5472.CAN-13-1318.

15.

Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein.

Carlo-Stella C, Dotti G, Mangoni L, Regazzi E, Garau D, Bonati A, Almici C, Sammarelli G, Savoldo B, Rizzo MT, Rizzoli V.

Blood. 1996 Oct 15;88(8):3091-100.

16.

Erythropoietin overcomes imatinib-induced apoptosis and induces erythroid differentiation in TF-1/bcr-abl cells.

Uchida M, Watanabe T, Kunitama M, Mori M, Kikuchi S, Yoshida K, Kirito K, Nagai T, Ozawa K, Komatsu N.

Stem Cells. 2004;22(4):609-16.

17.
18.

Expansion of granulocyte colony-stimulating factor/chemotherapy-mobilized CD34+ hematopoietic progenitors: role of granulocyte-macrophage colony-stimulating factor/erythropoietin hybrid protein (MEN11303) and interleukin-15.

Pierelli L, Scambia G, Bonanno G, Coscarella A, De Santis R, Mele A, Battaglia A, Fattorossi A, Romeo V, Menichella G, Mancuso S, Leone G.

Exp Hematol. 1999 Mar;27(3):416-24.

PMID:
10089903
19.
20.
Items per page

Supplemental Content

Support Center